Stockscreener 앱 받기
49.80
8.21%
3.78
시장 영업 전:
49.83
0.03
+0.06%
전일 마감가:
$46.02
열려 있는:
$45.93
하루 거래량:
1.38M
Relative Volume:
0.89
시가총액:
$3.18B
수익:
-
순이익/손실:
$-218.28M
주가수익비율:
-13.91
EPS:
-3.5803
순현금흐름:
$-186.55M
1주 성능:
+10.91%
1개월 성능:
+60.23%
6개월 성능:
+121.14%
1년 성능:
+10.40%
1일 변동 폭
$45.45
$50.16
1주일 범위
$40.38
$50.16
52주 변동 폭
$18.53
$50.16
베라 테라 Stock (VERA) Company Profile
명칭
Vera Therapeutics Inc
전화
650-770-0077
주소
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
VERA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
49.80 | 2.94B | 0 | -218.28M | -186.55M | -3.5803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
베라 테라 Stock (VERA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-16 | 개시 | BofA Securities | Buy |
| 2025-08-04 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-05-05 | 재개 | H.C. Wainwright | Buy |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2025-01-28 | 개시 | Goldman | Buy |
| 2024-11-21 | 개시 | Wells Fargo | Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-01-25 | 개시 | Oppenheimer | Outperform |
| 2024-01-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-12-18 | 개시 | Raymond James | Outperform |
| 2023-11-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-16 | 개시 | Guggenheim | Buy |
| 2023-01-04 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-01-04 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-07-12 | 개시 | JP Morgan | Overweight |
| 2022-05-02 | 개시 | H.C. Wainwright | Buy |
| 2022-04-19 | 개시 | Wedbush | Outperform |
모두보기
베라 테라 주식(VERA)의 최신 뉴스
Vera Therapeutics (NASDAQ:VERA) Trading Up 5.3%Still a Buy? - MarketBeat
Vera Therapeutics Sees Optimism as Analysts Boost Price Targets - timothysykes.com
Vera Therapeutics (NASDAQ:VERA) Hits New 12-Month HighHere's Why - MarketBeat
Avoiding Lag: Real-Time Signals in (VERA) Movement - news.stocktradersdaily.com
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Wedbush Maintains Vera Therapeutics (VERA) Neutral Recommendation - Nasdaq
Vera Therapeutics stock hits 52-week high at 47.12 USD By Investing.com - Investing.com Canada
Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets - ts2.tech
Wedbush Raises Price Target on Vera Therapeutics to $33 From $23, Keeps Neutral Rating - marketscreener.com
Vera Therapeutics, Inc. $VERA Shares Bought by Jump Financial LLC - MarketBeat
Vera Therapeutics Completes Successful Stock Offering - TipRanks
Vera Therapeutics Announces Follow-On Public Offering - TradingView — Track All Markets
Soviero Asset Management LP Invests $707,000 in Vera Therapeutics, Inc. $VERA - MarketBeat
188,422 Shares in Vera Therapeutics, Inc. $VERA Acquired by Norges Bank - MarketBeat
Vera Therapeutics Prices $261 Million Public Offering - marketscreener.com
Vera Therapeutics prices public offering at $42.50 per share By Investing.com - Investing.com Nigeria
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock - markets.businessinsider.com
Vera Therapeutics prices public offering at $42.50 per share - Investing.com
Vera Therapeutics prices public offering of Class A Common Stock at $42.50 per share - marketscreener.com
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock at $42.50 per Share - Quiver Quantitative
Polycythemia Vera Clinical Trial Pipeline Shows Potential with Active Contributions from 8+ Key Companies | DelveInsight - The Globe and Mail
Vera Therapeutics (NASDAQ:VERA) Shares Gap DownWhat's Next? - MarketBeat
Vera Therapeutics announces $200M public offering - MSN
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock - markets.businessinsider.com
Evercore ISI Group Maintains Vera Therapeutics (VERA) Outperform Recommendation - Nasdaq
Vera Therapeutics Plans Offering of Common Shares - marketscreener.com
Vera Therapeutics (VERA) proposes $200M Class A share sale with 15% underwriter option - Stock Titan
Evercore ISI Group Raises Price Target for Vera Therapeutics (VE - GuruFocus
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Bollard Group LLC Takes $1.51 Million Position in Vera Therapeutics, Inc. $VERA - MarketBeat
Assessing Vera Therapeutics (VERA) Valuation After Adding Industry Veteran James R. Meyers to Its Board - Sahm
Vera Therapeutics (NASDAQ:VERA) Price Target Raised to $73.00 - MarketBeat
Vera Therapeutics, Inc. $VERA Shares Sold by Affinity Asset Advisors LLC - MarketBeat
Vera Therapeutics Inc. (VERA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why Vera Therapeutics Stock is Climbing Higher - TipRanks
TD Cowen Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $73 - 富途牛牛
Schroder Investment Management Group Reduces Stock Position in Vera Therapeutics, Inc. $VERA - MarketBeat
Vera Therapeutics stock price target raised to $73 from $60 at TD Cowen - Investing.com UK
Vera Therapeutics exec Turner sells $400k in shares By Investing.com - Investing.com Canada
Vera Therapeutics exec Turner sells $400k in shares - Investing.com
Vera Therapeutics Executive Sells 10,000 Shares - TradingView
Will Vera Therapeutics Inc. stock reach Wall Street targets2025 Institutional Moves & Consistent Growth Stock Picks - Newser
Why Vera Therapeutics Inc. stock is trending among retail tradersMarket Volume Summary & Short-Term Trading Opportunity Alerts - Newser
Is Vera Therapeutics’ Recent 69% Surge Justified by Its Valuation in 2025? - Yahoo Finance
Vera Therapeutics rises 19.2% - MSN
Vera Therapeutics Stock Soars: Time to Buy? - StocksToTrade
Vera Therapeutics (VERA): Reassessing Valuation After Positive Phase 3 IgAN Data and Accelerated FDA Path - Yahoo Finance
Is Vera Therapeutics (VERA) Quietly Recasting Its Commercial Strategy With the Meyers Board Appointment? - Yahoo Finance
Vera Therapeutics (NASDAQ:VERA) Stock Price Up 6.7%Here's What Happened - MarketBeat
Vera Therapeutics, Inc. (VERA): A Top Gainer with Promising FDA Approvals - Meyka
Vera Therapeutics: Stock Rises As IgAN Approval Chances IncreaseI'm On Sidelines (VERA) - Seeking Alpha
베라 테라 (VERA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
베라 테라 주식 (VERA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Turner William D. | Chief Regulatory Officer |
Dec 08 '25 |
Sale |
45.31 |
10,000 |
453,053 |
22,500 |
1.08%
0.91%
자본화:
|
볼륨(24시간):